September 3, 2019

Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression

Key Points

Key points are not available for this paper at this time.

Abstract

The recent FDA approval of brexanolone may offer an effective treatment of moderate to severe PPD and has been shown to rapidly decrease depression symptoms.

AI से पूछें

Bookmark

AI से पूछें

Bookmark

Cite This Study

Powell et al. (Tue,) studied this question.

synapsesocial.com/papers/6a036f9290b35e5741aee09d https://doi.org/https://doi.org/10.1177/1060028019873320

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Prevalence of suicidality during pregnancy and the postpartum2005 · 801 citations
2The Columbia–Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings From Three Multisite Studies With Adolescents and Adults2011 · 5,058 citations
3The Hamilton Rating Scale for Depression2015 · 187 citations
4All-Cause Mortality in Women With Severe Postpartum Psychiatric Disorders2016 · 113 citations
5Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy2015 · 92 citations